A phase II trial to evaluate the safety and immunogenicity of PF-06482077

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 20-valent conjugate vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
Indications Pneumococcal infections
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Pfizer

29 Oct 2019 According to a Pfizer media release, the company will seek to present and publish outcomes from this clinical trial at a future date once safety and immunogenicity data has been analyzed following the completion of the four-dose regimen.
30 Apr 2019 According to a Pfizer media release, data from the study was presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases.
16 Apr 2019 Results evaluating the safety, tolerability and immunogenicity of PCV20 in adults presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com